A 3D model accurately mimicking the blood-brain barrier (BBB) in a laboratory environment has been successfully developed by ...

A new platform for studying neuroinflammatory diseases, utilizing advanced 3D bioprinting technology has been developed.

Understanding the pathogenesis of LID has contributed ... of dyskinesia as a motor complication in the course of Parkinson's disease (PD) includes a spectrum of involuntary movements schematically ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...